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Abstract
Background. Oligodendroglioma is a rare primary central nervous system (CNS) tumor with highly variable outcome and for which therapy is usually not curative. At present, little is known regarding the pathways involved with
progression of oligodendrogliomas or optimal biomarkers for stratifying risk. Developing new therapies for this
rare cancer is especially challenging. To overcome these challenges, the neuro-oncology community must be particularly innovative, seeking multi-institutional and international collaborations, and establishing partnerships with
patients and advocacy groups thereby ensuring that each patient enrolled in a study is as informative as possible.
Methods. The mission of the National Cancer Institute’s NCI-CONNECT program is to address the challenges and
unmet needs in rare CNS cancer research and treatment by connecting patients, health care providers, researchers,
and advocacy organizations to work in partnership. On November 19, 2018, the program convened a workshop on
oligodendroglioma, one of the 12 rare CNS cancers included in its initial portfolio. The purpose of this workshop
was to discuss scientific progress and regulatory challenges in oligodendroglioma research and develop a call to
action to advance research and treatment for this cancer.
Results. The recommendations of the workshop include a multifaceted and interrelated approach covering: biology and preclinical models, data sharing and advanced molecular diagnosis and imaging; clinical trial design;
and patient outreach and engagement.
Conclusions. The NCI-CONNECT program is well positioned to address challenges in oligodendroglioma care and
research in collaboration with other stakeholders and is developing a list of action items for future initiatives.
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Key Points
1 Patients with oligodendroglioma have highly variable outcome and therapy is
usually not curative.
2 Risk stratification biomarkers and pathways involved with resistance to therapy
and progression are being investigated.
3 The NCI-CONNECT Workshop provides a call to action to address challenges in
patient care and research.

Introduction and Background
Developing therapies for rare cancers of the central nervous
system (CNS) is especially formidable for several reasons.
First, unlike some other diseases, including many cancers,
there are few good preclinical models on which to build clinical trials. Second, the complexity of the CNS and potential
for therapy-induced injury poses strategic, pragmatic, and
ethical challenges. Third, there are inherent challenges in
both providing care and conducting clinical research. These
challenges include the potential for delays in diagnosis,
lack of well-defined standards of care, limited social and advocacy support, and difficulties in conducting clinical trials
because of low incidence compounded by the limited experience of health care providers, even those in academic
centers with specialized neuro-oncology programs. As these
cancers are extremely rare, it is difficult to recruit enough patients to statistically power a study. To overcome these multilayered challenges, the neuro-oncology community must
be particularly innovative, seeking multi-institutional and international collaboration, and establishing partnerships with
patients and advocacy groups thereby ensuring that each patient enrolled in a study is as informative as possible.

Responding to the Challenges
The Beau Biden Cancer Moonshot Program, part of the 21st
Century Cures Act, appropriated $1.7 billion toward cancer
care in 10 select areas, including patient engagement. The
National Cancer Institute (NCI) was granted support from
this program to focus specifically on adult rare CNS tumors
through the NCI-CONNECT program, housed in the NeuroOncology Branch in NCI’s Center for Cancer Research. The
program’s mission is to address the challenges and unmet
needs in adult rare CNS cancer research and treatment by
connecting patients, health care providers, researchers,
and advocacy organizations to work in partnership. The
program is first focusing on 12 types of rare CNS tumors,
each with less than 2,000 people diagnosed a year in the
United States. NCI-CONNECT has three program goals: (1)
develop an infrastructure across a network of national and
international sites to study select adult rare CNS tumors;
(2) collect, analyze, and share information to promote discovery and improve understanding of adult rare CNS tumors; and (3) build the network to facilitate the translation
of discoveries into new therapies through collaborative efforts to improve patient clinical outcomes.

As part of NCI-CONNECT, the Neuro-Oncology Branch
has undertaken a large international study, the “Outcomes
and Risk Study for Patients with Rare Brain and Spine
Tumors,” which aims to refine the molecular classification of these rare cancers so that physicians will be able
to give a more accurate prognosis to patients as well as
select more appropriate treatments that have a greater
likelihood of being effective in any individual tumor. It also
aims to uncover risk factors that might increase a person’s
chances of developing brain or spine cancer. Another
study, “Evaluation of the Natural History and Specimen
Banking for Patients with CNS Cancers,” was developed
to better understand brain and spinal cord tumors to uncover areas for future research. NCI-CONNECT also supports several treatment trials, including investigation of
the immunotherapy drug nivolumab for treating rare CNS
tumors, the multitargeted kinase inhibitor sunitinib for recurrent gliosarcomas and primary CNS sarcomas, the proteasome inhibitor marizomib for recurrent ependymoma,
and the antiangiogenic agent bevacizumab in combination
with carboplatin for recurrent ependymoma.
Partnering with advocacy groups and patients is critical
to NCI-CONNECT’s mission; to advance the understanding
of rare adult CNS cancers by establishing and fostering
patient–advocacy–provider partnerships and networks
to improve approaches to care and treatment. This could
lead to increased patient accrual to the program, care,
and studies, which take place at the National Institutes of
Health (NIH) Clinical Center or one of the more than 30 institutions in the Brain Tumor Trials Collaborative (BTTC)
network. An important contribution of NCI-CONNECT is
its convening power, that is, the ability to bring experts
in rare CNS cancers together to share insights, ideas,
and plans for collaboration. On November 19, 2018, NCICONNECT convened a workshop on oligodendroglioma,
one of the 12 rare CNS cancers included in its initial portfolio. (See https://ccr.cancer.gov/neuro-oncology-branch/
connect for the complete list.) This manuscript summarizes the proceedings of this workshop. Worldwide
neuro-oncology experts from different disciplines and advocacy partners met to discuss the molecular pathology of
oligodendrogliomas, preclinical models, clinical trial efficacy endpoints, and collaborative efforts in data sharing.
Presentations by leaders in the field on important areas
of scientific progress and associated challenges were followed by in-depth discussions by all participants divided
in working groups. Participants recognized the need to
combine data, resources, and samples to develop better
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Figure 1. Axial T2/FLAIR MRI images of patient with left
occipitoparietal oligodendroglioma WHO grade 2, IDH1 mutated,
1p19q codeleted with indolent course. (A) Incidental finding at age
39, followed with serial imaging without intervention. (B) Near total
resection at age 41 after slight increase in T2/FLAIR hyperintensity
and development of headaches, then followed without additional
treatment. (C) Slight increase in T2/FLAIR hyperintensity adjacent
to the surgical cavity at age 52 (13 years from initial imaging diagnosis; no prior radiation or chemotherapy).
  

B

treatments for patients with oligodendrogliomas. An action plan to address challenges in patient care and research was developed.

About Oligodendroglioma
Oligodendroglioma is a primary CNS tumor believed
to originate from oligodendroglial precursor cells.
Oligodendrogliomas are diffusely infiltrative gliomas molecularly defined by isocitrate dehydrogenase (IDH) mutation and codeletion of the short arm of chromosome 1
(1p) and the long arm of chromosome 19 (19q), according
to the World Health Organization (WHO) 2016 classification.1 Additionally, they are historically classified into
two grades, WHO grade II or low grade and grade III or
anaplastic, based on their histological characteristics.
Other common molecular alterations are described later
in this manuscript.2,3 Oligodendrogliomas represent less
than 10% of all gliomas.4 Whereas oligodendroglial tumors
share common molecular features and typically have a
better prognosis than astrocytic tumors, they still have
highly variable clinical outcomes even within the same
WHO grade (Figures 1 and 2). At present, little is known regarding the pathways involved with resistance to therapy
and progression of oligodendrogliomas or optimal biomarkers for stratifying risk.
Oligodendrogliomas occur most often in young adults
between the ages of 35 and 44 but can occur at any age.
They occur slightly more often in males and are rare in
children, in whom despite presenting classical histological features, the molecular characteristics differ from
adults (typically IDH/TERTp/1p19q wild type), with clinical
implications that are not fully understood.5,6 According to
the Central Brain Tumor Registry of the United States, an
estimated 11,757 people are living with this tumor in the
United States. The 5-year survival rate is 74.1%.4
Symptoms of oligodendroglioma depend on the size
and location of the tumor. The most common presenting

3

C
Figure 2. Axial T1 with contrast and T2/FLAIR MRI images of patient with left posterior temporal oligodendroglioma WHO grade 2,
IDH1 mutated, 1p19q codeleted with aggressive course. (A) Imaging
at age 28 after presenting with seizures; underwent biopsy without
further treatment. (B) Imaging at age 31 after biopsy demonstrating
transformation to anaplastic oligodendroglioma. Patient had received 2 years of therapy with temozolomide due to imaging progression detected 6 months after initial diagnosis. (C) Imaging
preresection (right) and postresection (left) at the time of 4th progression (age 37), after having received radiation, procarbazine and
lomustine; received subsequent treatment with re-irradiation and
with a PD-1 inhibitor 3 years later for new recurrence.
  

symptom is a seizure, which approximately 60% of patients
experience before being diagnosed.7 Other commonly
occurring symptoms include headaches, memory loss and
other cognitive difficulties, focal weakness and/or sensory
deficits, or problems with balance and movement. The first
intervention is surgery, which allows to make a tissue-based
diagnosis including molecular marker assessment; further,
surgery is a therapeutic measure and aims to remove as
much tumor as possible without causing more neurological
deficits. Current treatment guidelines are based on phase
3 clinical trials which were designed separately for grade II
and grade III tumors and before the establishment of molecular criteria for the diagnosis of oligodendroglioma. Upfront
treatment options for low-grade oligodendrogliomas include observation alone (typically for patients under the

4
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age of 40 with gross total resection of tumor) and radiation
with adjuvant chemotherapy for patients not meeting these
criteria (procarbazine/CCNU/vincristine or PCV, category
1; temozolomide, category 2B according to NCCN guidelines8). Anaplastic oligodendrogliomas are typically treated
with radiation and adjuvant PCV chemotherapy (category 1
according to NCCN guidelines8) or adjuvant temozolomide
with or without concurrent temozolomide.8–12 An ongoing
international phase 3 clinical trial (CODEL, NCT00887146)
is comparing the efficacy of radiotherapy with concomitant
temozolomide followed by adjuvant temozolomide, versus
radiotherapy with adjuvant PCV in patients with newly
diagnosed anaplastic gliomas and high-risk low-grade
gliomas with 1p/19q codeletion. Whether radiotherapy can
be deferred to prevent radiotherapy-induced neurotoxicity
in anaplastic oligodendrogliomas is currently being investigated in the POLCA trial, comparing upfront radiotherapy
plus PCV versus upfront PCV plus deferred radiotherapy
at progression (NCT02444000). Many questions remain
regarding treatment of oligodendrogliomas, including
the optimal time for initiation of therapy in low-grade tumors, the relative efficacy of PCV versus temozolomide, the
identification of favorable molecular markers beyond IDH
mutation13 and 1p19q codeletion14 (which are now diseasedefining and no longer prognostic within the histology), the
potential role of de-escalation of therapy for patients with
such favorable molecular markers, and the optimal therapy
for recurrent tumors.

Scientific Progress and Regulatory
Challenges in Oligodendroglioma
Research
To frame the discussion of the working groups, three important and separate areas of scientific progress and challenges were reviewed, as summarized below.

The Molecular Characteristics of
Oligodendroglioma: Implications for
Diagnosis and Prognosis
Presented by Daniel J. Brat, M.D., Ph.D., Northwestern
University Feinberg School of Medicine.
Oligodendrogliomas were first defined histopathologically in the 1920s. The oligodendrocyte had only
been defined as a type of glial cell in the 10 years prior.
Although treatment strategies have not evolved significantly over recent years, the ability to stratify risk has
improved, based increasingly on molecular alterations.
Although oligodendrogliomas are defined by the presence of IDH mutations and 1p/19q codeletion, they also
frequently harbor mutations in the TERT promoter, CIC,
FUBP1,3 and NOTCH1. In addition, these tumors are more
chemosensitive than their IDH1/2 mutated astrocytic counterparts, possibly due to the 1p/19q codeletion that accompanies the IDH mutations.15,16
Review of gliomas based on their mutational
status shows that oligodendrogliomas have a

specific profile, and there is little molecular overlap
among oligodendrogliomas, IDH mutant astrocytomas,
and IDH wild-type high-grade gliomas. Genes mutated
in oligodendrogliomas such as CIC, NOTCH1, FUBP1, are
typically not mutated in astrocytomas. These specific molecular fingerprints of glioma subtypes led the WHO in
2016 to distinguish between oligodendrogliomas and
astrocytomas based on their molecular characterization.
This also resulted in the recognition that the tumor previously called oligoastrocytoma did not have a molecular
signature and should not be used as a diagnosis when
molecular testing is available.1 This new paradigm has
led to an ability to establish reproducible and clinically
meaningful diagnoses that stratify risk based on molecular classes rather than on histological findings such as cell
morphology, nuclear atypia and vascular proliferation, or
necrosis. Leveraging this molecular characterization can
point to biomarkers and mechanisms that drive tumor progression so that therapies can be directed against them.
Within each molecular class of diffuse glioma, there is currently a desire to use molecular markers to further stratify
risk17 and serve as tools for grading. One study in Japan investigated two cohorts of patients with oligodendroglioma
whose tumors had been genetically sequenced.18 Based on
multivariate analysis, it was determined that incomplete
neurosurgical resection and the presence of NOTCH1 mutations—which are found specifically in oligodendrogliomas
but not in IDH mutant astrocytomas or molecularly defined
glioblastomas—were two independent predictors of poor
overall survival. Patients who had an extensive resection
and did not have NOTCH1 mutations had good clinical outcomes long-term. Based on these findings, Brat et al. are
developing clinical decision support algorithms to predict
patient outcomes and guide treatment decisions. Like the
Japanese cohort, Brat et al.’s analyses demonstrated that
NOTCH1 pathway inactivation and PI3K pathway activation are strongly associated with poor clinical outcome.19
Further analyses showed that every member of the NOTCH
pathway is upregulated dramatically in patients with prolonged survival, suggesting a pathway effect.
In addition to reviewing overall survival and progressionfree survival, Brat et al. analyzed endpoints associated with
disease progression, such as contrast enhancement on
magnetic resonance imaging (MRI), high-cellular density
in digitized histopathologic images, and increased cellular
proliferation. They searched for enrichment of specific mutations in those tumors with radiologic or pathologic feature of a higher grade. The contrast-enhancing tumors were
found to have NOTCH1 mutations, as well as shorter overall
survival. Similar correlations were found with regard to cell
density and proliferation. In comparison, the nonenhancing
tumors are genetically relatively silent. Although NOTCH1
mutations are important in the progression of this disease,
but other prognostic markers include PI3K pathway activation and loss of chromosomes 14q and 15q.

Evolution and Progression of Low-Grade Glioma
Presented by Joseph F. Costello, Ph.D., University of
California, San Francisco.
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Figure 3. Early origin of recurrence from a grade II oligodendroglioma. Tumor evolution inferred from mutations in a primary 1p19q
codeleted, IDH2 mutant low-grade oligodendroglioma and two
tumor samples from a subsequent tumor recurrence from the same
patient, resected years later (recurrence Y, recurrence G). The
phylogenetic tree is derived from somatic mutations from exome
sequencing of the tumor DNA samples. The length of each line in
the phylogenetic tree is proportional to the number of mutations.
The branch positions illustrate inferred points of evolutionary divergence among the samples. The IDH2 mutation is shared by all
three samples whereas a different CIC mutation is found in the initial sample versus in the two tumor samples at recurrence.
  

Costello et al. have focused on how oligodendrogliomas
initiate and progress through malignant transformation
(ie, change to a higher histological grade and development
of resistance to therapy). Their goal is to understand the
mechanism of malignant transformation to ultimately develop strategies to reduce its occurrence.
Using multiple samples from each tumor and accounting
for diversity in the genetic makeup in different parts of
the tumor, basic techniques of genetic phylogenies can
be traced back in time.20 In some cases, the first mutation
that occurred earlier in an individual patient’s tumor can
be determined. A phylogenetic tree can be constructed
that tracks the evolution in the mutations. In the example
provided in Figure 3 (tumor evolution in a primary 1p19q
codeleted, IDH2 mutant low-grade oligodendroglioma),
one can infer that in some cases the recurrence can differ
from the primary tumor (shares some mutations but has
a greater number of nonshared mutations). Piecing this
and other information together, a hypothesis of the steps
in the formation of a low-grade glioma can be constructed,
including improved understanding of epigenetic and metabolic effects, immune reprogramming, and immunosuppression, all induced by the IDH mutation. The cell cycle
is dysregulated through the TP53 mutation and results in
reduction in the ability of the cell to undergo apoptosis,
making it more resistant to therapy. Regulation of the cell
telomeres, and therefore mortality, is influenced by the
ATRX mutation in astrocytoma and the TERT promoter
mutation in oligodendroglioma.
Costello et al. have developed a model of low-grade
glioma initiation and malignant transformation with disease recurrence. There is great interest in the genetic characterization of cells that are left behind following surgical
resection as they can provide clues to the vulnerabilities
or resistance of the residual disease to which subsequent

treatment is directed. With malignant transformation,
tumors can recur as higher grade through spontaneous
genetic events or through chemotherapy-associated
increases in mutational burden including a profound
increase in mutations often referred to as hypermutation.21 Preclinical studies findings suggested that the
alkylating chemotherapy agent temozolomide might spur
a series of reactions that may lead to resistance to the
antitumor effect, consistent with findings from the genomic analysis of patient samples. However, this hypothesis still needs further clinical confirmation and enters in
conflict with the known clinical benefit of temozolomide
in oligodendroglial tumors. Thus, according to these preliminary findings, this agent could evolve from being cytotoxic to the tumor cells and beneficial to creating more
mutations that confer resistance at the time of relapse.
Costello et al. have shown that the signature of this chemotherapy can be seen in the exome sequencing of recurrent tumors.22 Hypermutation after temozolomide is
statistically associated with an increase in malignancy
grade in these studies; that is, the mutations created by
chemotherapy are contributing or driving the process
of malignant transformation. Further studies have
shown that although hypermutation most commonly
occurs in astrocytoma it can also be detected readily in
oligodendrogliomas. The mutations created by the drug
are promoting faster growth, because a critical checkpoint on cell growth is eliminated by mutations occurring
following chemotherapy, such as RB and AKT-mTOR
pathway mutations. However, the clinical significance
of these findings is still unclear. To date, the impact of a
hypermutator versus a nonhypermutator oligodendroglioma on patient’s overall survival has not been evaluated
prospectively, and clinical trials have shown improved
overall survival if chemotherapy is added early on to radiotherapy in oligodendrogliomas, raising the question of to
what extent these observations impact clinical outcome.
The Glioma Longitudinal AnalySiS (GLASS) Consortium
(https://www.glass-consortium.org/)
has
shown
an
increase in the number of CIC mutations after recurrence, suggesting that CIC is a marker of secondary progression. Further, almost all recurrent hypermutated
oligodendrogliomas appear to have a defect in the P53
pathway. In fact, analysis of the enrichment of pathway
mutations in hypermutated oligodendrogliomas reveals
that TP53 is the most enriched gene in these tumors and
likely a player in hypermutated oligodendroglioma. This
suggests that perhaps the cells that are hypermutated respond differently to therapy because TP53 has such a profound effect on their response.
Additional retrospective data on a small number of
cases suggest that the genotype of hypermutation is clinically relevant, although this requires further confirmation
in larger and prospective datasets. At recurrence, patients with a hypermutated tumor have a shorter overall
survival, suggesting that the hypermutator clone is more
aggressive than the standard grade III glioma when data
are adjusted for both age and subtype. The time between
the point of first chemotherapy and recurrence with a
hypermutator varies widely. Understanding the issues
of latency and tumor dormancy is the next challenge.
Studies with a greater range of patient outcomes are
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needed to understand the actual rate of hypermutation in
the treated population; preliminary data suggest the rate
is about 20%, but the number of cases analyzed to date is
small.

General Overview of Clinical Trial Efficacy
Endpoints
Presented by Paul G. Kluetz, M.D., U.S. Food and Drug
Administration.
The Federal Food, Drug, and Cosmetic Act (FD&C Act)
provides the framework for approval of new drugs based
on substantial evidence of efficacy and acceptable safety
for an indicated population. The Public Health Services Act
requires evidence that biologic products be safe, pure, and
potent for approval. The FDA Modernization Act clarified
that the review and approval of drugs and biologics use
a similar evidentiary framework, allowing for consistency
in trial design and endpoint selection for registration trials
to support cancer therapeutics. The traditional approval
pathway relies on clinical benefit endpoints or established
surrogate endpoints, in other words evidence of a “prolongation of life, a better life or an established surrogate.”
Accelerated approval is based on endpoints other than irreversible morbidity or mortality, and can rely on a surrogate endpoint reasonably likely to predict clinical benefit.23
Because there is often residual uncertainty regarding clinical benefit when using surrogate endpoints in the accelerated approval program, post-marketing trials are needed to
verify benefit. Direct measures of clinical benefit tend to be
clinical outcomes, such as feeling or functioning better, or
improvement in survival. In contrast, surrogate endpoints
are not directly measuring symptoms, function, or survival, but rather look to predict benefit. In oncology this
is most commonly based on control of tumor cell burden,
which can be directly measured either through the blood
in hematologic malignancy or through imaging of solid tumors. Because tumor measures are monitored and acted
upon in clinical practice (eg, changing therapies upon progression), response rate and progression-free survival are
considered strong endpoints suitable for either regular or
accelerated approval depending on the context and magnitude of effect.24
Clinical outcome assessments are used to quantify
symptoms or function. These data can come from several
sources, including clinician-reported outcomes, observerreported outcomes (someone other than the patient or
health care provider), patient-reported outcomes, or
performance-based outcomes.25 Wearable mobile technology tools may also provide an opportunity to gather
data related to activity and other components of function.
When evaluating the strength and limitations of various
types of efficacy endpoints, Dr. Kluetz stated that FDA will
consider what is being measured (ie, endpoint selection)
and whether it directly measures a clinical benefit (eg, survival, symptoms, or function) or whether it is a surrogate
endpoint. Another consideration is the accuracy of the
measure, its susceptibility to bias, subjectivity, or interpretation, and the accuracy of the timing of the event. For an
individual trial, the magnitude of effect on the endpoint is
an important consideration. For example, in a single-arm

trial of a chemotherapeutic agent treating patients with
oligodendroglioma, a high rate of rapid, deep, and durable
shrinkage of tumors across a cohort of patients would be
compelling evidence of antitumor effect due to the investigational agent, given malignant tumors do not typically
regress to a great extent on their own. Thus, treatment effect measured by tumor response can be a surrogate endpoint to support accelerated approval in the appropriate
setting (specific disease, large magnitude of the effect, durability of response).
Clinical benefit is determined based on the totality of
data within a given context. A critical component of the
totality of data is the safety profile of the product. Acute
and subacute safety and tolerability must be carefully
characterized, including clinician-reported adverse events,
dose modifications and, increasingly, patient-reported
symptomatic toxicities and their impact on function. The
agency will also consider other well-defined functional domains that affect one’s health-related quality of life, such
as cognition.

Moving the Field of Oligodendroglioma
Research Forward – Reports from
Working Groups
Workshop participants broke into four working groups to
discuss issues related to advancing the field through collaborative research efforts to establish better preclinical
models; data sharing and clinical research approaches,
such as advanced imaging; optimization of clinical trial designs; and promoting patient engagement.

Biology of Oligodendrogliomas and
Preclinical Models
Session Leads: Daniel P. Cahill, M.D., Ph.D., Harvard
Medical School and J. Gregory Cairncross, M.D., University
of Calgary.
Molecular diagnosis based on current WHO 2016
criteria allows a more reliable classification of
oligodendrogliomas and reflects tumor biology more accurately. This provides an opportunity for further research.
First, preclinical models are needed that emulate indolent
disease. It is difficult to propagate cell lines either in vitro
or these tumors in vivo. The limitations of animal models
include the long time to achieve tumor growth and the
relatively short lifespan of the animal, whereas some canine models that develop gliomas spontaneously are
promising.26 Induced pluripotent stem (iPS) cells provide
an opportunity to introduce the various mutations of the
disease to generate a faithful model that can be used for
in vitro studies. Recent success with creation of IDH mutant mouse models for astrocytoma could be adapted to
contain more oligodendroglioma-relevant genes.27–31
A second opportunity involves using clinical trial materials to develop correlative studies to understand the
biology of oligodendroglioma, in particular, to collect
image-guided tumor samples during longitudinal studies
that might provide clues about early progression and
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Collaborative Efforts in Data Sharing and
Incorporating Advanced Molecular Diagnosis
and Advanced Imaging in Low Grade Glioma
(LGG) Research
Session Leads: Terri S. Armstrong, Ph.D.,
NCI-CONNECT; Mark R. Gilbert, M.D., NCICONNECT; Roel G.W. Verhaak, Ph.D., Jackson
Laboratory for Genomic Medicine
Successful research networks require strong and welldefined leadership, centralized infrastructure, clearly defined policies (eg, data sharing, authorship), and funding.
For example, the Cancer Genome Atlas has been successful because of its infrastructure and large community
of scientists. The GLASS consortium35,44 is emerging as another robust effort in data aggregation and sharing. In each
of these cases, champions for this effort and a commitment
to inclusion and mutual value have brought success. NCICONNECT is well positioned to partner and collaborate
with such endeavors.
Future research efforts should consider the use of existing sources of data (alone or expanded) such as The
Surveillance, Epidemiology, and End Results Program
SEER https://seer.cancer.gov/ (some sites have samples) or case/control (eg, GICC,36 GLIOGENE37). Large cohorts, such as the Nurses’ Health Study (https://www.
nurseshealthstudy.org/about-nhs), have stored vast
amounts of clinical trial data that can be tapped for comparative controls. The AACR Project Genomics Evidence
Neoplasia Information Exchange (GENIE; https://www.
aacr.org/Research/Research/pages/aacr-project-genie.
aspx) provides a model platform for oligodendrogliomas.
As new data collection goes forward, patient-level information is needed and long-term follow-up with clinical
annotation is key. Although studies should always strive
to answer specific questions, data collection need not be
hypotheses-driven. For example, large companies collect
vast amounts of data that can later be evaluated for trends
or mined for profit. This is a model that should be emulated
in science. Ideally, molecular and imaging data should be
included in future data collection, noting that such efforts
require additional time and resources.

Collaboration will be essential to acquire large longitudinal sample collections, since historically sample sizes
have typically been small and it is difficult to achieve statistical power. Additional efforts are needed to explore the
value of serum- and CSF-derived biomarkers. In all cases,
annotated tissue sampling will be critical to answering
many questions.
A large amount of imaging data already exists and efforts are needed to combine these data. Although pre
and postoperative images tend to only include standard
sequences that are essential, consideration should be
given to adding advanced imaging studies such as perfusion/diffusion, PET (18F-FDG, 11C-MET, others), and 2-HG
spectroscopy when available, although many challenges
remain regarding their implementation, value, indications and standardization among centers. Workshop participants encouraged the use of the Brain Tumor Imaging
Protocol (BTIP) for standardization.38 Existing imaging infrastructure (ie, Quantitative Image Informatics for Cancer
Research [QIICR]) can be leveraged. Experience from the
French POLA effort to study rare tumors has shown that
the biggest challenge has been aggregating MRI images,
as some institutions do not save images and there are differences among institutions regarding what is saved and
what patient privacy protections are needed. Finally, in
cases where no tumor tissue is available, it may be possible to infer classification/genomic properties from radiologic images, which may enable retrospective sample
classification, although this remains speculative.

Clinical Trial Designs
Session Leads: Martin van den Bent, M.D., Ph.D., Erasmus
MC Cancer Institute, and Marta Penas-Prado, M.D.,
NCI-CONNECT.
Given the typical long survival of patients with oligodendroglioma, alternative clinical trial endpoints to
progression-free survival and overall survival are needed
that determine outcome and lead to more efficient trial
designs. Examples include imaging endpoints evaluating
growth trajectory, and clinical endpoints such as seizure
control, objective testing of cognitive function, instrumental
activities of daily living (ADLs), and symptom burden.39–43
At present, imaging endpoints evaluating growth trajectory
are an active subject of research by different groups but remain poorly defined and further studies are needed to validate them, particularly as related to posttreatment growth
rate changes. Use of composite endpoints, including evaluation of imaging trajectory in combination with one or more
clinical endpoints, should be considered for the design of
future clinical trials. Randomization as opposed to the use
of historical controls is also desirable for clinical trials that
will be of long duration, as the historical control comparison may be unreliable. Other trial designs to consider include Phase 0/proof-of-concept trials with tissue acquisition
and pharmacodynamic endpoints after administration of
experimental therapy to compensate for the lack of optimal
preclinical models. However, these trials are challenging to
implement and coordinate and are typically only feasible in
a small number of experienced centers.
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spatial heterogeneity. For example, do patients who fail
early have particular genetic alterations that could provide
a window into what predicts poor prognosis?19,32,33
A third opportunity lies in identifying druggable targets
for oligodendrogliomas. This could lead to preventive-type
strategies, for example, screening patients for high-risk
germline alterations34 and exposing people to a comparably safe drug early in adulthood to decrease their lifetime
risk of developing glioma.
These opportunities could be better pursued through
access to a central repository containing human and
animal tumor samples, prospective genomic analysis
conducted in parallel with large clinical trials, and prospective and continuous biospecimen monitoring to
search for biomarkers for patients in the indolent phase
of the disease.
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Inclusion and exclusion criteria for trials can be better
informed through molecular characterization as opposed
to classical clinical factors (extent of resection, age), for
example, to select patients who should not delay upfront
therapy (those at greatest risk of progression due to a highrisk molecular signature). Importantly, the working group
emphasized the need for contemporary tissue sampling in
trials for recurrent oligodendroglioma to assess molecular
changes over time.
The group also recommended that tumor tissue and
blood collection be made mandatory for future trials.
Having tissue collected upfront would facilitate future analyses as more information becomes available,
rather than trying to obtain tumor tissue retrospectively
to analyze recently discovered biomarkers once a prospective study is completed. Given the low incidence of
oligodendrogliomas, there should be initiatives launched
to combine efforts that are not only multi-institutional but

also international, recognizing regulatory, and logistical
challenges. One potential alternative to conducting collaborative international trials creating an oligodendroglioma
consortium similar to the AGILE consortium for glioblastoma (www.gcaresearch.org/gbm-agile/), which has led
to the development of an international adaptive platform
trial with an external contract research organization (CRO)
in charge of supporting the trial (NCT03970447). However,
for international studies, it is easier to pool data than to
exchange tumor tissue samples or collaborate on trials
given the increasingly complex regulatory environment
for material transfer agreements and trial sponsorship.
Existing longitudinal studies of cancer cohorts have relied
on patients prospectively opting into data and specimen
collection, which can eliminate some of the regulatory obstacles to seeking permission retrospectively or obtaining
institutional permission to do so. Despite these challenges,
the NCI-CONNECT program provides an opportunity for

  
Biology and Preclinical Models
• Develop appropriate models that recapitulate indolent disease
• Analyze tissue longitudinally and identify and validate molecular markers of poor outcome in patients
with early failure for introduction in clinical trials (as selection or stratification criteria)
• Identify druggable targets

Patient Outreach and Engagement
• Develop standardized information about diagnosis and meaning of molecular testing
using lay language to share across advocacy groups
• Provide information and training for health care providers
on educational resources for patients and families
• Unify patient registries

Data Sharing and Advanced Molecular Diagnosis
and Imaging

Biology and
Preclinical
Models

• Create research networks with well-defined leadership,
centralized infrastructure, clearly defined policies (data sharing,
authorship) and funding

Data Sharing
and Advanced
Molecular
Diagnosis and
Imaging

• Use untapped sources of data (SEER, GICC, GLIOGENE,
Nurses’ Health Study, AACR GENIE)
• Collect hypothesis-generating rather than only hypothesis-driven
data
• Collaborate to obtain large longitudinal sample collection with
clinical annotation, including tissue, serum and CSF-derived
biomarkers
• Standardize and combine imaging data, including advanced
techniques (perfusion/diffusion, PET, 2-HG) and correlate with
molecular data

Clinical Trial Design
• Develop alternative endpoints to PFS and OS and composite endpoints: growth
trajectory, seizure control, cognitive function, instrumental ADLs, symptom burden
• Use randomization rather than historical controls
• Consider Phase 0 designs with tissue acquisition and PD endpoints
• Obtain contemporary tissue in trials for recurrence
• Mandate tissue collection for future molecular studies
• Overcome roadblocks for international collaboration

Figure 4.
  

Workshop recommendations.

Patient
Outreach and
Engagement

Clinical Trial
Design
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Patient Outreach and Engagement
Session Leads: Brittany Cordeiro, Terri
S. Armstrong, Ph.D., and Mark R. Gilbert, M.D.,
NCI-CONNECT
Patients need more standardized and reliable information
about diagnosis and treatment for their own consumption
and for sharing across groups. For example, patients might
be misleadingly told that they have the “good tumor”
when being diagnosed with a 1p/19q codeletion and not
receive the same prognostic information as others with the
same diagnosis. Along with discussions about prognosis,
guidance regarding impact of the disease on daily life is
also critical, including issues with loss of independence (inability to return to previous work, driving restrictions) and
family planning for patients in their reproductive years.
Contradictory or inaccurate information can not only influence treatment decisions but also deter research participation. For example, patients need to understand the still
uncertain clinical implications of the preliminary findings
regarding hypermutation and how that might or might not
influence treatment decisions. In addition, standardized
information and training for providers is a critical need.
NCI-CONNECT can be a valuable and trusted resource in
communicating accurate information to the patient and
provider communities about research, diagnosis, and new
treatment options. Finally, patient registries are an important resource for patients to both provide and receive critical clinical and research information.

Conclusions, Recommendations and
Action Plan
An important contribution of NCI-CONNECT is its
ability to bring experts in rare CNS cancers together
to share insights, ideas, and plans for collaboration.
Oligodendroglioma is one of the 12 rare CNS cancers included in the initial NCI-CONNECT portfolio. Although
oligodendrogliomas typically have better prognoses than
other primary brain tumors, they still have highly variable clinical outcomes, and little is known about the pathways involved with progression or the optimal markers for
stratifying risk. Current therapies are effective in controlling tumor growth for prolonged periods of time in many
instances, but they are usually not curative, and both the
tumor itself and the treatments are often linked to longterm sequalae and increased symptom burden with a negative impact on quality of life.
This report summarizes the discussion and recommendations of the Oligodendroglioma Workshop held on
November 19, 2018 and provides a call to action to address the challenges noted in oligodendroglioma care
and research. The recommendations of the workshop are
summarized in Figure 4 and include a multifaceted and
interrelated approach covering four distinct areas: biology

and preclinical models, data sharing and advanced molecular diagnosis and imaging, clinical trial design, and patient outreach and engagement.
The NCI-CONNECT program is well positioned to address
many of these needs in collaboration with other stakeholders,
and a list of action items emanated from the workshop and is
currently being worked on. The Natural History study with its
longitudinal collection of clinical data along with tumor tissue
and germline samples is serving as a platform for interaction
with investigators from other sites to unify patient registries
and collaborate on tumor tissue analysis (from both newly
diagnosed and recurrent tumors) as well as germline analysis
from other large tumor repositories.
Another contribution of the NCI-CONNECT program is a
clinical trial infrastructure in which only industry support to
provide the experimental agent/s is necessary. Conducting
multi-institutional collaborative umbrella or basket trials
for oligodendrogliomas together with other rare CNS tumors sharing the same molecular features is possible.
Finally, partnering with advocacy groups and patients is
critical to NCI-CONNECT, and development of informational resources for patients and health care providers falls
within its mission.
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